Cost Utility of Telaprevir–PR (Peginterferon–Ribavirin) Versus Boceprevir–PR and Versus PR Alone in Chronic Hepatitis C in The Netherlands

Overview of attention for article published in Applied Health Economics and Health Policy, August 2014

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 33 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 721 followers.

#HealthEconJA Cost Utility of Telaprevir–PR (Peginterferon–Ribavirin) Versus Boceprevir–PR and Versus PR Alone i... http://t.co/BwpM28799C

Reply Repost Favourite